M&A Deal Summary

Hepion Pharmaceuticals Acquires Ciclofilin Pharmaceuticals

On May 31, 2016, Hepion Pharmaceuticals acquired life science company Ciclofilin Pharmaceuticals for 17M USD

Acquisition Highlights
  • This is Hepion Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Hepion Pharmaceuticals’ largest (disclosed) transaction.
  • This is Hepion Pharmaceuticals’ 1st transaction in the United States.
  • This is Hepion Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2016-05-31
Target Ciclofilin Pharmaceuticals
Sector Life Science
Buyer(s) Hepion Pharmaceuticals
Deal Type Merger
Deal Value 17M USD

Target

Ciclofilin Pharmaceuticals

San Diego, California, United States
Ciclofilin Pharmaceuticals, Inc. is a biopharmaceutical company specializing in development of cyclophilin inhibitors, an emerging class of drugs for infectious, inflammatory, and degenerative diseases.

Search 199,031 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Hepion Pharmaceuticals

Edison, New Jersey, United States
Category Company
Founded 2013
Sector Life Science
Employees13
DESCRIPTION

Hepion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies. Hepion Pharmaceuticals was founded in 2013 and is based in Edison, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal